Form 4: Immunic CFO Glenn Whaley Reports Stock Option Repricing

Glenn Whaley, CFO of Immunic, Inc., reports changes in beneficial ownership due to the repricing of employee stock options.

Summary

• On March 6, 2024, Glenn Whaley, the Chief Financial Officer of Immunic, Inc., filed a Form 4.
• The filing reports changes in beneficial ownership related to derivative securities, specifically stock options.
• On March 4, 2024, Immunic's stockholders approved a proposal to reduce the exercise price of eligible employee stock options to the greater of $1.72 or 110% of the closing price on a future repricing date.
• The Board of Directors set the repricing date as March 4, 2024, and determined that the exercise price of all eligible options would be repriced to $1.72 per share.
• The Form 4 reflects the cancellation of existing eligible options and the reissuance of those options at the new exercise price of $1.72 per share.
• Whaley was granted 220,000 stock options at an exercise price of $1.72.
• The original vesting schedules and expiration dates of the options remain unchanged.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a change in beneficial ownership due to a previously approved stock option repricing. The repricing itself could be seen as a positive sign that the company is taking steps to incentivize employees, but it could also be interpreted as a reflection of past stock performance.

Positives

• The repricing of stock options could incentivize employees, including the CFO, by making the options more valuable.
• The repricing was approved by stockholders, suggesting broad support for the measure.
• The CFO was granted 220,000 stock options at an exercise price of $1.72.

Industry Context

Stock option repricing is a tool companies use to re-incentivize employees when the stock price has fallen below the exercise price of existing options. This is common in the biotech industry, which can be volatile and subject to significant price swings based on clinical trial results and regulatory approvals.

Comparison to Industry Standards

• Stock option repricing is a relatively common practice, particularly in volatile sectors like biotechnology.
• Many companies, especially smaller cap firms, use stock options as a key component of compensation packages to attract and retain talent.
• The specific terms of the repricing, such as the new exercise price and the retention of the original vesting schedule, are typical considerations in these situations.

Stakeholder Impact

• Shareholders may view the repricing as a positive step to motivate employees and align their interests with the company's success.
• Employees holding stock options will benefit from the lower exercise price, potentially increasing the value of their options.
• The repricing has no immediate impact on customers, suppliers, or creditors.

Key Dates